Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)

NCT03598699 is registered in ClinicalTrials.gov with AxeroVision, Inc. as lead sponsor.

NCT NCT03598699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Lead sponsor
AxeroVision, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 26, 2018
Completion date
January 9, 2019
Enrollment
102 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye